A prospective, randomized, controlled parallel-group clinical trial has demonstrated that surgical intervention provides significantly greater functional improvement and spasticity reduction than botulinum toxin type A injections for adult patients living with poststroke upper extremity spasticity. Conducted across two third-level hospitals, the twelve-month study tracked motor function, hygiene, pain intensity, emotional status, quality of life, and caregiver burden between the two therapeutic modalities. The trial results established that individuals undergoing surgical intervention attained superior improvements on established clinical scales alongside higher overall patient satisfaction rates compared to those treated with botulinum toxin.
The clinical study addresses an extensive global health burden, given that more than ninety-three million people worldwide currently live with persistent stroke sequelae. Although poststroke spasticity in the upper limbs is usually managed through botulinum toxin type A injections, surgical intervention represents an effective and safe approach. Historically, surgery has been restricted almost exclusively to patients exhibiting the most severe presentations of spasticity. Furthermore, prior to this investigation, no prospective clinical trial had directly compared the clinical outcomes and therapeutic effects of surgery against botulinum toxin type A in this patient population.
To compare these therapeutic options directly, investigators designed a randomized, controlled, parallel-group clinical trial involving adult stroke survivors eligible for surgery who were recruited from two third-level hospitals in southern Spain. Eligible participants were assigned to one of two active treatment arms, comprising twenty-one patients in the surgical intervention cohort and twenty-four patients in the botulinum toxin cohort. Both groups were monitored over a twelve-month follow-up window to evaluate functional changes, hygiene status, physical comfort, emotional parameters, and overall care demands.
The primary objective of the trial was to compare functional, hygienic, and pain outcomes alongside effects on emotional status, quality of life, and care burden between surgery and botulinum toxin type A. To analyze continuous outcome measures across repeated assessments over twelve months, the investigators utilized mixed-effects generalized linear models. These models specified fixed effects for treatment group, time, and the interaction between group and time, with adjustments made for baseline values and a random intercept incorporated for each subject to account for within-patient correlation.
For ordinal clinical endpoints, the researchers employed mixed-effects cumulative-link models incorporating a complementary log–log link function, which were also adjusted for baseline participant scores. This statistical methodology allowed the study team to rigorously evaluate differences between surgical treatment and botulinum toxin injections across continuous motor scales as well as graded categorical measures, while properly accounting for baseline values and the repeated-measures structure of the trial.
The clinical results revealed statistically significant differences between the two treatment cohorts over the twelve-month evaluation. Patients in the surgery group achieved significantly greater improvements in Fugl-Mayer assessment scores and modified Ashworth spasticity scale ratings compared to those in the botulinum toxin group. In addition to these measured functional gains, a significantly higher patient satisfaction rate was observed among participants who underwent surgical intervention compared to participants managed with botulinum toxin.
The comparative trial also evaluated the wider effects of the interventions on daily life, pain severity, and support networks. Unlike botulinum toxin type A, surgery produced a significant reduction in overall caregiver burden and led to significant improvements in patient-reported pain assessed through the 36-item Short Form Health Survey. However, the two treatments did not significantly differ in their impact on emotional status or overall quality of life, indicating comparable effects across broader psychological and systemic health domains.
Alongside these clinical benefits, the investigation documented intervention-associated safety outcomes, recording a postsurgery complication rate of 23.8 percent, with incomplete deformity correction requiring repeat surgery representing the most frequent adverse event. Classified as Level I evidence and retrospectively registered on ClinicalTrials.gov under registration number NCT06392633 on 30 April 2024, the study concluded that surgery offers significantly greater spasticity reduction, functional improvement, and care burden reduction than botulinum toxin type A. The authors noted that these findings support a greater role for upper extremity surgeons within multidisciplinary care teams, while emphasizing that future trials with longer follow-ups are warranted to explore outcome durability.
Subject of Research: Surgical intervention compared to botulinum toxin for poststroke upper extremity spasticity
Article Title: Surgery versus botulinum toxin for poststroke upper extremity spasticity: a prospective randomized trial on function, care, and quality of life
Article References: Hurtado-Olmo, P., González-Santos, Á., Ávila-Cabreja, J. A., Del Olmo-Iruela, L., Castro-Ropero, B., Ariza-García, A., & Hernández-Cortés, P. (2026). Surgery versus botulinum toxin for poststroke upper extremity spasticity: a prospective randomized trial on function, care, and quality of life. Journal of Orthopaedics and Traumatology. https://doi.org/10.1186/s10195-026-00982-y
Image Credits: AI Generated
DOI: 10.1186/s10195-026-00982-y
Keywords: poststroke spasticity, upper extremity spasticity, surgical intervention, botulinum toxin type A, randomized controlled trial, Fugl-Mayer scale, modified Ashworth scale, caregiver burden, SF-36 pain score, stroke sequelae, patient satisfaction, parallel-group trial, mixed-effects generalized linear models, cumulative-link models, postsurgical complications, incomplete deformity correction, quality of life, third-level hospitals
News Source: Ophelia Keating. (November 16, 2026). Surgery Surpassed Botulinum Toxin for Poststroke Upper Extremity Spasticity in Trial. Scienmag.



